[1] Fokkens W J, Lund V J, Hopkins C, et al. European position paper on rhinosinusitis and nasal polyps 2020[J]. Rhinology, 2020, 58(Suppl 29): 1-464.
[2] Huang K W, Yang T, Xu J Y, et al. Prevalence, risk factors, and management of asthma in China: a national cross-sectional study[J]. Lancet, 2019, 394(10196): 407-418.
[3] Benjamin M R, Stevens W W, Li N, et al. Clinical characteristics of patients with chronic rhinosinusitis without nasal polyps in an academic setting[J]. J Allergy Clin Immunol Pract, 2019, 7(3): 1010-1016.
[4] Won H K, Kim Y C, Kang M G, et al. Age-related prevalence of chronic rhinosinusitis and nasal polyps and their relationships with asthma onset[J]. Ann Allergy Asthma Immunol, 2018, 120(4): 389-394.
[5] Takabayashi T, Schleimer R P. Formation of nasal polyps: the roles of innate type 2 inflammation and deposition of fibrin[J]. J Allergy Clin Immunol, 2020, 145(3): 740-750.
[6] Bu X T, Wang M, Luan G, et al. Integrated miRNA and mRNA expression profiling reveals dysregulated miRNA-mRNA regulatory networks in eosinophilic and non-eosinophilic chronic rhinosinusitis with nasal polyps[J]. Int Forum Allergy Rhinol, 2021, 11(8): 1207-1219.
[7] Striz I, Golebski K, Strizova Z, et al. New insights into the pathophysiology and therapeutic targets of asthma and comorbid chronic rhinosinusitis with or without nasal polyposis[J]. Clin Sci (Lond), 2023, 137(9): 727-753.
[8] Brescia G, Alessandrini L, Zanotti C, et al. Histopathological and hematological changes in recurrent nasal polyposis[J]. Int Forum Allergy Rhinol, 2019, 9(7): 813-820.
[9] Castillo J A, Plaza V, Rodrigo G, et al. Chronic rhinosinusitis with nasal polyps and allergic rhinitis as different multimorbid treatable traits in asthma[J]. J Allergy Clin Immunol Glob, 2023, 2(4): 100134.
[10] Sella G C P, Tamashiro E, Sella J A, et al. Asthma is the dominant factor for recurrence in chronic rhinosinusitis[J]. J Allergy Clin Immunol Pract, 2020, 8(1): 302-309.
[11] Tiotiu A, Novakova P, Guillermo G, et al. Management of adult asthma and chronic rhinitis as one airway disease[J]. Expert Rev Respir Med, 2021, 15(9): 1135-1147.
[12] Wang M, Bu X T, Luan G, et al. Distinct type 2-high inflammation associated molecular signatures of chronic rhinosinusitis with nasal polyps with comorbid asthma[J]. Clin Transl Allergy, 2020, 10: 26.
[13] Matucci A, Bormioli S, Nencini F, et al. Asthma and chronic rhinosinusitis: how similar are they in pathogenesis and treatment responses?[J]. Int J Mol Sci, 2021, 22(7): 3340.
[14] Chen C L, Yao Y, Pan L, et al. Common fibrin deposition and tissue plasminogen activator downregulation in nasal polyps with distinct inflammatory endotypes[J]. J Allergy Clin Immunol, 2020, 146(3): 677-681.
[15] Zhu Y L, Esnault S, Ge Y, et al. Airway fibrin formation cascade in allergic asthma exacerbation: implications for inflammation and remodeling[J]. Clin Proteomics, 2022, 19(1): 15.
[16] Heissig B, Salama Y, Takahashi S, et al. The multifaceted role of plasminogen in inflammation[J]. Cell Signal, 2020, 75: 109761.
[17] Takabayashi T, Kato A, Peters A T, et al. Increased expression of factor ⅩⅢ-a in patients with chronic rhinosinusitis with nasal polyps[J]. J Allergy Clin Immunol, 2013, 132(3): 584-592.e4.
[18] Jo A, Choi T G, Han J Y, et al. Age-related increase of collagen/fibrin deposition and high PAI-1 production in human nasal polyps[J]. Front Pharmacol, 2022, 13: 845324.
[19] De Lorenzi V, Sarra Ferraris G M, Madsen J B, et al. Urokinase links plasminogen activation and cell adhesion by cleavage of the RGD motif in vitronectin[J]. EMBO Rep, 2016, 17(7): 982-998.
[20] Hopkins C. Chronic rhinosinusitis with nasal polyps[J]. N Engl J Med, 2019, 381(1): 55-63.
|